The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein

English version České info

Dengue viruses are mosquito-borne flaviviruses that circulate in nature as four distinct serotypes (DENV1-4). These emerging pathogens are responsible for more than 100 million human infections annually. Severe clinical manifestations of disease are predominantly associated with a secondary infection by a heterotypic DENV serotype. The increased risk of severe disease in DENV-sensitized populations significantly complicates vaccine development, as a vaccine must simultaneously confer protection against all four DENV serotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of ongoing vaccine development efforts. However, a recent large clinical trial of a candidate live-attenuated DENV vaccine revealed low protective efficacy despite eliciting a neutralizing antibody response, highlighting the need for a better understanding of the humoral immune response against dengue infection. In this study, we sought to identify epitopes recognized by serotype-specific neutralizing antibodies elicited by monovalent DENV1 vaccination. We constructed a panel of over 50 DENV1 structural gene variants containing substitutions at surface-accessible residues of the envelope (E) protein to match the corresponding DENV2 sequence. Amino acids that contribute to recognition by serotype-specific neutralizing antibodies were identified as DENV mutants with reduced sensitivity to neutralization by DENV1 immune sera, but not cross-reactive neutralizing antibodies elicited by DENV2 vaccination. We identified two mutations (E126K and E157K) that contribute significantly to type-specific recognition by polyclonal DENV1 immune sera. Longitudinal and cross-sectional analysis of sera from 24 participants of a phase I clinical study revealed a markedly reduced capacity to neutralize a E126K/E157K DENV1 variant. Sera from 77% of subjects recognized the E126K/E157K DENV1 variant and DENV2 equivalently (<3-fold difference). These data indicate the type-specific component of the DENV1 neutralizing antibody response to vaccination is strikingly focused on just two amino acids of the E protein. This study provides an important step towards deconvoluting the functional complexity of DENV serology following vaccination.

Vyšlo v časopise: The Type-Specific Neutralizing Antibody Response Elicited by a Dengue Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein. PLoS Pathog 9(12): e32767. doi:10.1371/journal.ppat.1003761
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003761

Souhrn

Zdroje

1. BhattS, GethingPW, BradyOJ, MessinaJP, FarlowAW, et al. (2013) The global distribution and burden of dengue. Nature 496 ((7446)): 504–7.

2. HalsteadSB (2007) Dengue. Lancet 370: 1644–1652.

3. SrikiatkhachornA, RothmanAL, GibbonsRV, SittisombutN, MalasitP, et al. (2011) Dengue–how best to classify it. Clin Infect Dis 53: 563–567.

4. GuzmanMG, AlvarezM, HalsteadSB (2013) Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol 158 ((7)): 1445–59.

5. VaughnDW, GreenS, KalayanaroojS, InnisBL, NimmannityaS, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2–9.

6. KyleJL, HarrisE (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71–92.

7. PereraR, KuhnRJ (2008) Structural proteomics of dengue virus. Curr Opin Microbiol 11: 369–377.

8. MukhopadhyayS, KuhnRJ, RossmannMG (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3: 13–22.

9. WangPG, KudelkoM, LoJ, SiuLY, KwokKT, et al. (2009) Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS One 4: e8325.

10. MackenzieJM, WestawayEG (2001) Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75: 10787–10799.

11. LorenzIC, KartenbeckJ, MezzacasaA, AllisonSL, HeinzFX, et al. (2003) Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 77: 4370–4382.

12. WelschS, MillerS, Romero-BreyI, MerzA, BleckCK, et al. (2009) Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5: 365–375.

13. GillespieLK, HoenenA, MorganG, MackenzieJM (2010) The endoplasmic reticulum provides the membrane platform for biogenesis of the flavivirus replication complex. J Virol 84: 10438–10447.

14. LiL, LokSM, YuIM, ZhangY, KuhnRJ, et al. (2008) The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319: 1830–1834.

15. ZhangY, KaufmannB, ChipmanPR, KuhnRJ, RossmannMG (2007) Structure of immature West Nile virus. J Virol 81: 6141–6145.

16. ZhangY, CorverJ, ChipmanPR, ZhangW, PletnevSV, et al. (2003) Structures of immature flavivirus particles. EMBO J 22: 2604–2613.

17. ElshuberS, AllisonSL, HeinzFX, MandlCW (2003) Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. J Gen Virol 84: 183–191.

18. StadlerK, AllisonSL, SchalichJ, HeinzFX (1997) Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 71: 8475–8481.

19. YuIM, ZhangW, HoldawayHA, LiL, KostyuchenkoVA, et al. (2008) Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 319: 1834–1837.

20. MukhopadhyayS, KimBS, ChipmanPR, RossmannMG, KuhnRJ (2003) Structure of West Nile virus. Science 302: 248.

21. KuhnRJ, ZhangW, RossmannMG, PletnevSV, CorverJ, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717–725.

22. ZhangX, ShengJ, PlevkaP, KuhnRJ, DiamondMS, et al. (2013) Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A

23. StiasnyK, KiermayrS, HolzmannH, HeinzFX (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80: 9557–9568.

24. PiersonTC, FremontDH, KuhnRJ, DiamondMS (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229–238.

25. PiersonTC, DiamondMS (2012) Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2: 168–175.

26. WhiteheadSS, BlaneyJE, DurbinAP, MurphyBR (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518–528.

27. Belmusto-WornVE, SanchezJL, McCarthyK, NicholsR, BautistaCT, et al. (2005) Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189–197.

28. HeinzFX, HolzmannH, EsslA, KundiM (2007) Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25: 7559–7567.

29. MasonRA, TaurasoNM, SpertzelRO, GinnRK (1973) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539–544.

30. MonathTP, NicholsR, ArchambaultWT, MooreL, MarchesaniR, et al. (2002) Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533–541.

31. WilliamsKL, WahalaWM, OrozcoS, de SilvaAM, HarrisE (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12–20.

32. WilliamsKL, Sukupolvi-PettyS, BeltramelloM, JohnsonS, SallustoF, et al. (2013) Therapeutic Efficacy of Antibodies Lacking FcgammaR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies. PLoS Pathog 9: e1003157.

33. ShresthaB, AustinSK, DowdKA, PrasadAN, YounS, et al. (2012) Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology 427: 127–134.

34. LaiCJ, GoncalvezAP, MenR, WernlyC, DonauO, et al. (2007) Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 81: 12766–12774.

35. ShresthaB, BrienJD, Sukupolvi-PettyS, AustinSK, EdelingMA, et al. (2010) The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823.

36. Sukupolvi-PettyS, AustinSK, EngleM, BrienJD, DowdKA, et al. (2010) Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol 84: 9227–9239.

37. RoehrigJT (2003) Antigenic structure of flavivirus proteins. Adv Virus Res 59: 141–175.

38. Sukupolvi-PettyS, AustinSK, PurthaWE, OliphantT, NybakkenGE, et al. (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 12816–12826.

39. BeltramelloM, WilliamsKL, SimmonsCP, MacagnoA, SimonelliL, et al. (2010) The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271–283.

40. RoehrigJT, BolinRA, KellyRG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.

41. CrillWD, RoehrigJT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769–7773.

42. CrillWD, ChangGJ (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975–13986.

43. StiasnyK, BrandlerS, KosslC, HeinzFX (2007) Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol 81: 11526–11531.

44. BeasleyDW, AaskovJG (2001) Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279: 447–458.

45. SchieffelinJS, CostinJM, NicholsonCO, OrgeronNM, FontaineKA, et al. (2010) Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.

46. VogtMR, MoeskerB, GoudsmitJ, JongeneelenM, AustinSK, et al. (2009) Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 83: 6494–6507.

47. ZouG, KukkaroP, LokSM, NgJK, TanGK, et al. (2012) Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. Antiviral Res 95: 216–223.

48. de AlwisR, SmithSA, OlivarezNP, MesserWB, HuynhJP, et al. (2012) Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109: 7439–7444.

49. de AlwisR, BeltramelloM, MesserWB, Sukupolvi-PettyS, WahalaWM, et al. (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188.

50. SmithSA, de AlwisR, KoseN, DurbinAP, WhiteheadSS, et al. (2013) Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis 207 ((12)): 1898–908.

51. DejnirattisaiW, JumnainsongA, OnsirisakulN, FittonP, VasanawathanaS, et al. (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745–748.

52. TeohEP, KukkaroP, TeoEW, LimAP, TanTT, et al. (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4: 139ra183.

53. SmithSA, ZhouY, OlivarezNP, BroadwaterAH, de SilvaAM, et al. (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86: 2665–2675.

54. MehlhopE, NelsonS, JostCA, GorlatovS, JohnsonS, et al. (2009) Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6: 381–391.

55. GarciaG, ArangoM, PerezAB, FonteL, SierraB, et al. (2006) Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. J Clin Virol 37: 53–57.

56. KuraneI, HebblewaiteD, BrandtWE, EnnisFA (1984) Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol 52: 223–230.

57. LaoprasopwattanaK, LibratyDH, EndyTP, NisalakA, ChunsuttiwatS, et al. (2007) Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J Infect Dis 195: 1108–1116.

58. BarrettAD, TeuwenDE (2009) Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 21: 308–313.

59. HalsteadSB, ThomasSJ (2010) Japanese encephalitis: new options for active immunization. Clin Infect Dis 50: 1155–1164.

60. SabinAB (1952) Research on dengue during World War II. Am J Trop Med Hyg 1: 30–50.

61. GromowskiGD, RoehrigJT, DiamondMS, LeeJC, PitcherTJ, et al. (2010) Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape. Virology 407: 237–246.

62. WahalaWM, DonaldsonEF, de AlwisR, Accavitti-LoperMA, BaricRS, et al. (2010) Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog 6: e1000821.

63. BrienJD, AustinSK, Sukupolvi-PettyS, O'BrienKM, JohnsonS, et al. (2010) Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84: 10630–10643.

64. KliksSC, NisalakA, BrandtWE, WahlL, BurkeDS (1989) Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40: 444–451.

65. CalisherCH, KarabatsosN, DalrympleJM, ShopeRE, PorterfieldJS, et al. (1989) Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70 ((Pt 1)) 37–43.

66. De MadridAT, PorterfieldJS (1974) The flaviviruses (group B arboviruses): a cross-neutralization study. J Gen Virol 23: 91–96.

67. SabchareonA, WallaceD, SirivichayakulC, LimkittikulK, ChanthavanichP, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559–1567.

68. DurbinAP, KirkpatrickBD, PierceKK, SchmidtAC, WhiteheadSS (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29: 7242–7250.

69. WhiteheadSS, FalgoutB, HanleyKA, BlaneyJEJr, Jr, MarkoffL, et al. (2003) A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 77: 1653–1657.

70. WhiteheadSS, HanleyKA, BlaneyJEJr, GilmoreLE, ElkinsWR, et al. (2003) Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21: 4307–4316.

71. ZhangY, ZhangW, OgataS, ClementsD, StraussJH, et al. (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12: 1607–1618.

72. DurbinAP, McArthurJH, MarronJA, BlaneyJE, ThumarB, et al. (2006) rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2: 255–260.

73. DurbinAP, McArthurJ, MarronJA, BlaneyJEJr, ThumarB, et al. (2006) The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2: 167–173.

74. NelsonS, JostCA, XuQ, EssJ, MartinJE, et al. (2008) Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 4: e1000060.

75. OliphantT, NybakkenGE, AustinSK, XuQ, BramsonJ, et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828–11839.

76. OliphantT, NybakkenGE, EngleM, XuQ, NelsonCA, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149–12159.

77. PiersonTC, SanchezMD, PufferBA, AhmedAA, GeissBJ, et al. (2006) A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346: 53–65.

78. PiersonTC, XuQ, NelsonS, OliphantT, NybakkenGE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135–145.

79. KlassePJ, SattentauQJ (2001) Mechanisms of virus neutralization by antibody. Curr Top Microbiol Immunol 260: 87–108.

80. AndrewesCH, ElfordWJ (1933) Observations on Anti-Phage Sera. I: “The Percentage Law”. British Journal of Experimental Pathology 14: 367–376.

81. DowdKA, JostCA, DurbinAP, WhiteheadSS, PiersonTC (2011) A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog 7: e1002111.

82. LokSM, KostyuchenkoV, NybakkenGE, HoldawayHA, BattistiAJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312–317.

83. SaboMC, LucaVC, RaySC, BukhJ, FremontDH, et al. (2012) Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology 422: 174–184.

84. WitzJ, BrownF (2001) Structural dynamics, an intrinsic property of viral capsids. Arch Virol 146: 2263–2274.

85. LinJ, LeeLY, RoivainenM, FilmanDJ, HogleJM, et al. (2012) Structure of the Fab-labeled “breathing” state of native poliovirus. J Virol 86: 5959–5962.

86. DurbinAP, WhiteheadSS, ShafferD, ElwoodD, WanionekK, et al. (2011) A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 5: e1267.

87. LinTY, DowdKA, ManhartCJ, NelsonS, WhiteheadSS, et al. (2012) A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus. J Virol 86: 3501–3512.

88. CrillWD, HughesHR, DeloreyMJ, ChangGJ (2009) Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4: e4991.

89. WahalaWM, KrausAA, HaymoreLB, Accavitti-LoperMA, de SilvaAM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103–113.

90. WahalaWM, HuangC, ButrapetS, WhiteLJ, de SilvaAM (2012) Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86: 4019–4023.

91. StrengellM, IkonenN, ZieglerT, JulkunenI (2011) Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 6: e25848.

92. WalkerLM, SimekMD, PriddyF, GachJS, WagnerD, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6: e1001028.

93. MoorePL, RanchobeN, LambsonBE, GrayES, CaveE, et al. (2009) Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog 5: e1000598.

94. MurphyMK, YueL, PanR, BoliarS, SethiA, et al. (2013) Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth. PLoS Pathog 9: e1003173.

95. ReschW, ZaslavskyL, KiryutinB, RozanovM, BaoY, et al. (2009) Virus variation resources at the National Center for Biotechnology Information: dengue virus. BMC Microbiol 9: 65.

96. KaufmannB, VogtMR, GoudsmitJ, HoldawayHA, AksyukAA, et al. (2010) Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 107: 18950–18955.

97. NybakkenGE, OliphantT, JohnsonS, BurkeS, DiamondMS, et al. (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437: 764–769.

98. JohnsonJE (2003) Virus particle dynamics. Adv Protein Chem 64: 197–218.

99. CockburnJJ, Navarro SanchezME, FretesN, UrvoasA, StaropoliI, et al. (2012) Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20: 303–314.

100. AustinSK, DowdKA, ShresthaB, NelsonCA, EdelingMA, et al. (2012) Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8: e1002930.

101. Ansarah-SobrinhoC, NelsonS, JostCA, WhiteheadSS, PiersonTC (2008) Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381: 67–74.

102. ModisY, OgataS, ClementsD, HarrisonSC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986–6991.

103. HuangCC, CouchGS, PettersenEF, FerrinTE (1996) Chimera: An Extensible Molecular Modeling Application Constructed Using Standard Components. Pacific Symposium on Biocomputing 1.

104. ZhangX, ShengJ, PlevkaP, KuhnRJ, DiamondMS, et al. (2013) Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A 110: 6795–6799.

105. FibriansahG, NgTS, KostyuchenkoVA, LeeJ, LeeS, et al. (2013) Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J Virol 87: 7585–7592.

106. MukherjeeS, LinTY, DowdKA, ManhartCJ, PiersonTC (2011) The infectivity of prM-containing partially mature West Nile virus does not require the activity of cellular furin-like proteases. J Virol 85: 12067–12072.

107. ObaraCJ, DowdKA, LedgerwoodJE, PiersonTC (2013) Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses. Virology 437: 20–27.